아미노글리코사이드 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Aminoglycosides Market size is expected to reach USD 3.57 Billion in 2034 from USD 2.42 Billion (2025) growing at a CAGR of 4.39% during 2026-2034.

The Global Aminoglycosides Market has experienced steady growth due to the persistent prevalence of bacterial infections and hospital-acquired infections worldwide. Aminoglycosides, a class of antibiotics effective against Gram-negative bacteria, remain critical in severe infection management. Increasing incidences of sepsis, tuberculosis, and complicated urinary tract infections have sustained demand. Additionally, the rise in antimicrobial resistance has reinforced the importance of combination antibiotic therapies where aminoglycosides are often used as adjunct treatments in clinical practice.

Key growth drivers include expanding healthcare infrastructure in emerging economies and increased hospital admissions. Government initiatives promoting infection control programs and greater access to essential medicines also support market expansion. Pharmaceutical companies are investing in research to improve drug formulations and reduce toxicity concerns, which historically limited broader usage. The growing need for cost-effective and reliable antibiotics in developing countries further contributes to sustained demand.

Future prospects for the aminoglycosides market appear stable, though moderate in growth rate. Innovation in drug delivery systems, such as inhalation therapies for respiratory infections, could unlock new application areas. However, regulatory scrutiny and antimicrobial stewardship programs may restrict overuse. The market is expected to benefit from ongoing research into novel aminoglycoside derivatives with enhanced efficacy and reduced side effects, ensuring continued relevance in infectious disease treatment.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Neomycin
• Tobramycin
• Gentamicin
• Amikacin
• Paromomycin
• Streptomycin
• Other Products

By Application

• Bacterial Infection
• Tuberculosis
• Other Applications

By Route Of Administration

• Injectable
• Oral
• Topical
• Ophthalmic

By End Use

• Hospitals And Clinics
• Research And Academic Institutes
• Homecare Settings
• Other End Users

COMPANIES PROFILED

• Aurobindo Pharma, Bausch Health Companies, Cipla, Fresenius Kabi, Kremoint Pharma Bliss GVS Pharma, Meiji Seika Pharma Meiji Holdings, Novartis, Perrigo Company, Pfizer, Sun Pharmaceutical Industries, Sanofi, Teva Pharmaceuticals

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AMINOGLYCOSIDES MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Neomycin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Tobramycin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Gentamicin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Amikacin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Paromomycin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Streptomycin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Other Products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AMINOGLYCOSIDES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Bacterial Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Tuberculosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AMINOGLYCOSIDES MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Ophthalmic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AMINOGLYCOSIDES MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Hospitals And Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Research And Academic Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Homecare Settings Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL AMINOGLYCOSIDES MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Application
  • 8.2.3 By Route Of Administration
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Application
  • 8.3.3 By Route Of Administration
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Application
  • 8.4.3 By Route Of Administration
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Application
  • 8.5.3 By Route Of Administration
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Application
  • 8.6.3 By Route Of Administration
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL AMINOGLYCOSIDES INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Aurobindo Pharma
  • 10.2.2 Bausch Health Companies
  • 10.2.3 Cipla
  • 10.2.4 Fresenius Kabi
  • 10.2.5 Kremoint Pharma (Bliss GVS Pharma)
  • 10.2.6 Meiji Seika Pharma (Meiji Holdings)
  • 10.2.7 Novartis
  • 10.2.8 Perrigo Company
  • 10.2.9 Pfizer
  • 10.2.10 Sun Pharmaceutical Industries
  • 10.2.11 Sanofi
  • 10.2.12 Teva Pharmaceuticals